Aging · 2021 · 177 citations · 31 references
MedicineBioinformaticsOncologyCancer PharmacologyChemotherapyMolecular OncologyCancer Cell SignalingChemotherapy ResistanceColorectal CancerMalignant NeoplasmsSignal Transduction In CancerTumor Suppressor GenesColorectal Cancer ChemopreventionOxaliplatin-based TherapyOxidative Stress In CancerSensitivityTherapeutic Resistance Mechanisms
, and silencing KIF20A also suppressed NUAK1 activation, while a NUAK1 agonist (ETC-1002) could reverse the oxaliplatin sensitivity of KIF20A-silenced cells. Moreover, silencing NUAK1 up-regulated the expression of PP1β, down-regulated the phosphorylation of downstream GSK3βSer9, suppressed the nuclear import of Nrf2, inhibited the expression of a ferroptosis key negative regulatory protein (GPX4), and blocked cellular resistance. Applying a Nrf2 agonist (oltipraz) also reversed the oxaliplatin sensitivity of NUAK1-silenced cells. Therefore, cellular ferroptosis may be inhibited via the KIF20A/NUAK1/PP1β/GPX4 pathway in CRC cells, which may underly the resistance of CRC to oxaliplatin.
31
Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1
Evanna L. Mills, Dylan G. Ryan, Hiran A. Prag et al. · Nature · 2018 · 1.8K citations
Metallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis
Xiaofang Sun, Xiaohua Niu, Ruochan Chen et al. · Hepatology · 2016 · 735 citations · Full text
Medicine, Oncology, Pharmacology +15